Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Acad Dermatol ; 65(3): 493-514, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21839316

ABSTRACT

Vitiligo is a common skin disorder that results in depigmentation. With the appropriate management, many patients can minimize disease progression, attain repigmentation, and achieve cosmetically pleasing results. There are numerous medical and surgical treatments aimed at repigmentation; therapies for depigmentation are available for patients with recalcitrant or advanced disease. The use of cosmetics at all stages of treatment may be vital to the patient's quality of life. Understanding all the available options helps choose the appropriate treatment plan and tailor it to your patient. Part II of this two-part series on vitiligo discusses the indications for, evidence behind, and adverse effects associated with many of the therapies used for vitiligo. Both conventional medical and surgical options are discussed in addition to several alternative and promising new therapies.


Subject(s)
Vitiligo , Humans , Vitiligo/surgery , Vitiligo/therapy
2.
J Am Acad Dermatol ; 65(3): 473-491, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21839315

ABSTRACT

Vitiligo is an acquired pigmentary disorder of unknown etiology that is clinically characterized by the development of white macules related to the selective loss of melanocytes. The prevalence of the disease is around 1% in the United States and in Europe, but ranges from less than 0.1% to greater than 8% worldwide. A recorded predominance of women may reflect their greater willingness to express concern about cosmetically relevant issues. Half of all patients develop the disease before 20 years of age. Onset at an advanced age occurs but is unusual, and should raise concerns about associated diseases, such as thyroid dysfunction, rheumatoid arthritis, diabetes mellitus, and alopecia areata. Generalized vitiligo is the most common clinical presentation and often involves the face and acral regions. The course of the disease is unpredictable and the response to treatment varies. Depigmentation may be the source of severe psychological distress, diminished quality of life, and increased risk of psychiatric morbidity. Part I of this two-part series describes the clinical presentation, histopathologic findings, and various hypotheses for the pathogenesis of vitiligo based on past and current research.


Subject(s)
Vitiligo , Diagnosis, Differential , Humans , Quality of Life , Vitiligo/diagnosis , Vitiligo/epidemiology , Vitiligo/etiology , Vitiligo/pathology
4.
Arch Dermatol ; 145(11): 1313-6, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19917964

ABSTRACT

BACKGROUND: Gastrointestinal stromal tumors (GISTs) harbor gain-of-function mutations of the c-kit tyrosine kinase receptor. Imatinib mesylate is an inhibitor of c-kit and is indicated in the treatment of chronic myeloid leukemia and GISTs. Reported adverse effects of imatinib include hypopigmentation, depigmentation, and hyperpigmentation. Although the exact mechanism by which these occur is unclear, it is likely that inhibition of c-kit leads to downstream inhibition of the tyrosinase gene promoter and thus to inhibition of pigment production. OBSERVATIONS: A 45-year-old woman with a history of multiple dysplastic nevi and lentigines was diagnosed as having familial GIST syndrome. Treatment with imatinib mesylate was started in an attempt to decrease the tumor load. Three months after treatment initiation, the patient noted a decrease in the number of pigmented lesions, lightening of the skin in her genital area, and graying of her terminal hair. CONCLUSIONS: The potential association between a specific genetic mutation and pigmentation changes secondary to imatinib therapy may account for the variety in presentation of this potential side effect. Further genetic studies paired with melanocyte-specific or c-kit-specific stains of affected tissue are warranted to better understand the relationship between the genetic mutation and the effect of imatinib on pigmentation.


Subject(s)
Antineoplastic Agents/administration & dosage , Gastrointestinal Stromal Tumors/complications , Gastrointestinal Stromal Tumors/drug therapy , Lentigo/complications , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Benzamides , Chemotherapy, Adjuvant , Colectomy/methods , Dysplastic Nevus Syndrome/complications , Dysplastic Nevus Syndrome/drug therapy , Dysplastic Nevus Syndrome/genetics , Female , Follow-Up Studies , Gastrointestinal Stromal Tumors/genetics , Gastrointestinal Stromal Tumors/surgery , Humans , Imatinib Mesylate , Lentigo/drug therapy , Lentigo/genetics , Middle Aged , Risk Assessment , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...